Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Semaglutide versus dulaglutide once a week in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial